Monitoring Guidelines for Non-interventional Studies

Similar documents
Approaches to targeted monitoring. and evidence (or not) to support them

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Innovative Clinical Development Solutions

Reducing the Time to Market with an eclinical System

Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials

Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight

Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses

inventivhealthclinical.com The Goal: Reducing Uncertainty A Word on RBM

Clinical Trial Performance Metrics

Risk-Based Monitoring Improves Site Performance and Investigator Satisfaction

Risk Based Monitoring Initiative RISK-BASED MONITORING UPDATE - VOLUME 1

Determining How to Make Data Review More Efficient by Utilizing Visualization Tools. Susan Doleman, Replimune Inc.

Evolving Role of the Data Manager

FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?

NIS Considerations - Bulgaria

Index of Standard Operating Procedures for all research Sponsored by the UHL

Risk-Based Monitoring Update Volume V

Quality Control in Clinical Trials Blinding, Clinical Event Committees, Core Labs, and Data Standards

We set things in motion and keep them moving. Metronomia Clinical Research Services

Risk-Based Monitoring in Clinical Trials: A Cross-Functional Approach

Corporate Presentation. October 2017

How to organize a Clinical Theranostics Trial?

KEY CONSIDERATIONS AND CHALLENGES OF EDC IN THE IMPLEMENTATION AND STATISTICS OF CLINICAL TRIALS

High Quality or Poor Quality DB

Detailing key considerations and challenges of EDC to enable users to reap the cost, time and quality benefits

Conducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency

Standard Operating Procedure

BIOCLINICA CLINICAL DATA MANAGEMENT

BEST PRACTICES GUIDE COMPLYING WITH THE ICH E6(R2) ADDENDUM

Phase 1 studies and The Over- Volunteering Prevention System (TOPS)

Index of Standard Operating Procedures for all research Sponsored by the UHL

Risk-Based Monitoring Update Volume IV

St. Luke s University Health Network

NON-INTERVENTIONAL STUDY ABSTRACT FOR EXTERNAL DISCLOSURE

Trial Services. The allround trial specialist in cardiology Leading since cardialysis.com

ICONik Patient Centric Monitoring The ICON s risk-based monitoring approach

INTRODUCING CLINIC AUTOMATION IN A PHASE I UNIT WITH END-TO-END E-SOURCE DATA PROCESSING

Annex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO

RBM Risk Based Monitoring GCP Training 12/SEP/2015. Gabor Kiss Synexus Hungary2015

Approaches to Risk-Based Quality Management Quality by Design/Quality Systems

Less is the New More. Alternative models for Source Data Verification (SDV) Anna Wojciuk Clinical Data Manager Biometrics Department KCR

ADB Consulting & CRO Inc.

Risk-Based Monitoring - Prospective from CRO

LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office

Navigating the Convergence of Payer and Regulator Evidence Requirements Opportunities and Challenges

Investigator Site File Index (CTIMP)

Welcome. Thank you for joining us. Irina Moissiu, Director Client Relations Laurie Furiness, EVP Operations & Consulting Services

Code break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.

Aims and challenges of clinical trial data sharing

Trial Manager often = Trial Monitor Trial Team Impact on resources Build in efficiency and quality from beginning (pre-funding) Risk Assessment <->

RSNA/SNM/FDA. Management of Image Data Workflow. Two Topic Imaging Workshop: Standards for Imaging Endpoints in Clinical Trials

ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL

Clinical trials from CRA s point of view

MCRA Clinical More Than Your Average CRO. Clinical Project Management. Site Management and Study Monitoring. Data Management. Auxiliary Services

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

Adopting Site Quality Management to Optimize Risk-Based Monitoring

Standard Operating Procedure for Archiving

Innovative strategies to improve R&D ROI

Author Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document

Regulatory Requirements

STANDARD OPERATING PROCEDURE SOP 725 CAPACITY, CAPABILITY AND RISK ASSESSMENT OF TRIALS HOSTED BY NNUH

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Guidelines for Setting Up a Regulatory Binder

A Regulatory Approach to Validation of the CDM

Current Trends at FDA: Implications for Data Requirements

Achieves International Standards

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

Expanded Access and the Individual Patient IND

FACT SHEET. A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies.

Author Signature: Date: 10 October 2017 The author is signing to confirm the technical content of this document

Use of computerised equipment, software and systems in clinical research

STANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down

Expanded Access to Investigational Imaging Drugs

II. Clinical Trial Regulation Challenges for National Competent Authorities Perspective of BfArM Thomas Sudhop, MD

EU Regulatory Perspective

Creating the ideal Approach to gain Balance between effective Oversight and Micromanaging

Pharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri

Recruitment of Subjects Best Practices

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Risk-Based Monitoring Considerations in Rare Diseases Trials

Quality Assurance in Clinical Trials Introduction

The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)

4.1. Target Accrual Rate: The Target Accrual Goal divided by the Expected Duration (in days) of the trial.

Welcome to Module 2. In this module, we will be providing an overview of the TransCelerate Methodology process and toolkit, comparing off-site,

UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH SUPPORT OFFICE

Clinical Data in Business Intelligence

Aepodia is a team of experts with more than 15 years

Ensuring Data Quality in Animal Health Sponsor Perspective

Assessing the Quality {Company s} Rela7onship with its Inves7ga7ve Sites

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 5.0, February 2, 2009

Assessing the Quality {Company s} Rela7onship with its Inves7ga7ve Sites

Policy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017

ecoa SOLUTIONS Eliminate ecoa complexity so you can move ahead quickly

OCTC 2012 CRO Selection

Regulatory and ethics bodies involved in approval process. CA - Registration requirements for clinical trials

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

Position Description Clinical Research Associate

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014

Transcription:

Monitoring Guidelines for Non-interventional Studies

NIS Considerations We all know that monitoring is key to ensure patient safety and data quality However, non-interventional studies (NIS) are not randomised controlled clinical trials Monitoring of NIS needs to be tailored to accomodate a range of NIS considerations including the study design, regulatory requirements, study duration, number of sites and patients and study outcomes

NIS Considerations Why are NIS different? Drug commercially available and used according to marketing authorisation Not protocol driven Retrospective and prospective designs Country-specific requirements Breach of data privacy is greatest study risk to patient, not IMP-related SARs

Monitoring Options When designing an NIS monitoring plan, need to consider: Regulatory requirements - e.g., monitoring of NIS is a legal requirement in Spain Study design and purpose/endpoints Study size, duration and global footprint Therapeutic area Business policy - The degree of risk the business is willing to accept e.g., a 0% monitoring policy significantly increases the risk that any data generated will not be credible or submissable (e.g., RMP) or publishable

Monitoring Options On-site monitoring On-site & remote monitoring (Hybrid) Remote monitoring Phone calls, emails, ecrf etc No monitoring

On-site Monitoring Classic gold standard On-site monitoring every 4 to 8 weeks 100% SDV of X% of CRFs NIS Opportunity Can be used for short-term prospective NIS such as PASS where data credibility is paramount Challenge Impractical for large, long-term prospective studies High cost and resource implications

No Monitoring Not an option for interventional clinical trials NIS Opportunity Effective for retrospective NIS based on patient information collected from managed core databases NIS Challenge Not effective for prospective NIS as need to ensure/assure quality/ credibility of data

Remote Monitoring NIS Opportunity Allows for frequent contact with sites to provide support and reinforce appropriate performance Reduced resource and cost requirements Can be used to trigger on-site monitoring NIS Challenge Needs to be conducted by an experienced CRA for it be effective Doesn t account for on-site auditing of data - credibility of data therefore unknown

Hybrid Monitoring NIS Opportunity Allows for frequent contact with sites to provide support and reinforce appropriate performance Reduced resource and cost requirements Can be used to trigger on-site monitoring Schedule periodic site visits to address site needs and assess data quality

Hybrid Monitoring NIS Challenge Needs to be conducted by an experienced CRA for it be effective Sponsor-site relationship is more effective when a single point of contact is maintained (may be impacted by staff turnover) Need to clearly define triggers for on-site monitoring prior to study start e.g., - Suspected fraud - Rate of enrollment - Missing CRFs - Number of data queries

Overview of NIS Monitoring Approaches 100% remote monitoring 100% on-site monitoring 0% monitoring Hybrid monitoring Short-term Prospective NIS PASS First choice for most NIS Retrospective data mining

References Weishaar RE. Efficient and Cost-Effective Monitoring for Observational Studies. Journal of Clinical Studies. January 2011